Respiratory Diseases

 
ME/CFS Rates No Different After COVID-19 Infection than After Other Acute Infection-Like Illnesses
July 24, 2024

The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.

Respiratory Virus Vaccines: AAFP Board Chair on Patient Eligibility, How to Combat Misinformation this Season
July 19, 2024

Encouraging patients to reach out with questions may lead more to roll up their sleeves this season, Tochi Iroku-Malize, MD, told Patient Care.

Respiratory Virus Vaccine Update: AAFP Board Chair Details ACIP 2024-25 Recommendations
July 12, 2024

Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.

FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults
June 27, 2024

The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.

Phase 3 Trial of Combination Flu/SARS-CoV-2 Vaccine Meets All Primary Endpoints: Moderna
June 11, 2024

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.

FDA Approves First mRNA Vaccine Against RSV for Adults Aged ≥60 Years: Daily Dose
June 07, 2024

Your daily dose of the clinical news you may have missed.

FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years
June 03, 2024

mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes
May 22, 2024

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.